CME on Measuring Tumour Response in Radiology
Columbia Asia Radiology had organized a CME on “Measuring tumour response in radiology” on 28th November 2018 at Columbia Asia Hospital – Yeshwanthpur. CME was conducted by Dr. Anita Nagadi – Lead Head and Neck (Oncology)
The CME focused on the importance of the assessment of tumour burden as a feature of the clinical evaluation of cancer therapeutics. Both tumour shrinkage and disease progression are useful endpoints in clinical trials.
Since RECIST was published in 2000, many investigators, cooperative groups, industry, and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions and issues have arisen which have led to the development of a revised RECIST guideline.
RECIST 1.1 was introduced in the year 2009 which had several changes incorporated including a reduction in the number of lesions to be assessed, a new measurement method to classify lymph nodes as pathologic or normal, the clarification of the requirement to confirm a complete response (CR) or partial response (PR) and new methodologies for more appropriate measurement of disease progression.
Considering the importance of imaging in detection, staging, and evaluation of tumor response to treatment, Columbia Asia Radiology Group took the initiative of organizing a CME at Columbia Asia Hospital, Yeshwanthpur where all the above changes were dealt in detail with suitable examples.
In addition to RECIST 1.1, mRECIST, CHOI criteria and LUGANO criteria were also discussed. This was followed by an interactive Q/A session which highlighted the impact of these tumour response criteria on patient care and management in oncology.
The CME turned out to be very insightful for all the participants.
